Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Savara Inc (NQ: SVRA )

4.510 +0.250 (+5.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,099,839
Open 4.370
Bid (Size) 4.460 (2)
Ask (Size) 4.620 (2)
Prev. Close 4.260
Today's Range 4.150 - 4.520
52wk Range 3.115 - 5.700
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q2 2024
SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+3.20%
+3.20%
1 Month
-8.89%
-8.89%
3 Month
-6.63%
-6.63%
6 Month
-9.80%
-9.80%
1 Year
+16.84%
+16.84%

More News

Read More
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
From Savara Inc.
Via Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q1 2024
Via InvestorPlace
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
SVRA Stock Earnings: Savara Beats EPS for Q4 2023
Via InvestorPlace
Savara Inc. (NASDAQ: SVRA) Making Surprising Moves in Monday Session
Via Investor Brand Network
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Savara to Present at the Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara to Present at the Citizens JMP Life Sciences Conference
From Savara Inc.
Via Business Wire
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara to Present at Two Upcoming Healthcare Conferences
From Savara Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.